New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:30 EDTMCP, COH, GOOG, FSLR, AGN, CREE, STRI, MAPP, HLF, IBM On The Fly: Closing Wrap
Stocks on Wall Street were higher following better than expected earnings from tech giants IBM (IBM) and Google (GOOG). Near midday, the House voted to extend the debt limit until May 19, as expected, and the markets did not react to the news. Eyes on the Street are focused on this evening's report from Nasdaq's largest component, Apple (AAPL)... ECONOMIC EVENTS: In the U.S., the light economic calendar included the Home Price Index, which showed prices rose 0.6% in November, versus expectations for an increase of 0.7%. Also of note, the International Monetary Fund lowered its outlook for 2013 global output growth to 3.5% from 3.6%... COMPANY NEWS: IBM shares gained $8.64, or 4.41%, to $204.72 after its earnings report and guidance exceeded expectations. Google similarly reported earnings that beat consensus. A number of firms increased their price targets on shares, including Jefferies taking their target up to $875. Google advanced $38.63, or 5.5%, to $741.50 following its earnings report... Herbalife (HLF) was again in the news as Greenlight Capital's quarterly letter to investors made the rounds this afternoon. There was some speculation that the letter contained a veiled reference to a short position in Herbalife, however, The Wall Street Journal reported that Greenlight's David Einhorn told investors he does not currently have any bet on the stock. However, Einhorn admitted to profiting from a short position in Herbalife held in 2012 that has since been closed. Shares of Herbalife were down $1.13, or 2.56%, to $43.01 on the day... Among notable companies moving after reporting earnings were Cree (CREE), up $7.38, or 22.05%, to $40.85 after beating expectations, and Coach (COH), down $9.93, or 16.36%, to $50.75 after its earnings fell short of expectations and its Q4 SSS fell 2%... MAJOR MOVERS: Among notable gainers was MAP Pharmaceuticals (MAPP), which rose $9.13, or 58.6%, to $24.71 after it was announced last night that the company had agreed to be acquired by Allergan (AGN) for $25 per share. Allergan shares fell $1.10, or 1.04%, to $104.65 following the announcement. Among notable losers was Molycorp (MCP), which fell 95c, or 10.76%, to $7.88 after disclosing that the company sees Q4 and 1H13 production below expectations and shares were downgraded at Dahlman Rose. Also lower were shares of STR Holdings (STRI), down 79c, or 25.48%, to $2.31 after announcing last night that it expects to lose First Solar (FSLR) as a customer and shares were downgraded to Hold at Craig-Hallum... INDICES: The Dow was up 66.96, or 0.49%, to 13,779.17; the Nasdaq was up 10.49, or 0.33%, to 3,153.67; and the S&P 500 was up 2.22, or 0.15%, to 1,494.78.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 16, 2015
09:33 EDTGOOGeBay second week of November SSS up 0.4%, ChannelAdvisor says
Subscribe for More Information
08:07 EDTAGNAllergan reports Phase I/II interim data of Bimatoprost SR IOP therapy
Subscribe for More Information
07:50 EDTIBMUBS to hold a conference
Subscribe for More Information
06:33 EDTAGNPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
06:27 EDTGOOGYandex extends Google antitrust battle to EU, Bloomberg reports
Subscribe for More Information
05:42 EDTIBMXilinx, IBM announce strategic collaboration
IBM (IBM), and Xilinx (XLNX) announced a multi-year strategic collaboration to enable higher performance and energy-efficient data center applications through Xilinx FPGA-enabled workload acceleration on IBM POWER-based systems. IBM and Xilinx, through a private signed agreement and collaboration through the OpenPOWER Foundation, are teaming to develop open acceleration infrastructures, software and middleware to address emerging applications such as machine learning, network functions virtualization, or NFV, genomics, high performance computing, or HPC, and big data analytics. As part of the IBM and Xilinx strategic collaboration, IBM Systems Group developers will create solution stacks for POWER-based servers, storage and middleware systems with Xilinx FPGA accelerators for data center architectures such as OpenStack, Docker, and Spark. IBM will also develop and qualify Xilinx accelerator boards into IBM Power Systems servers. Xilinx is developing and will release POWER-based versions of its leading software defined SDAccel Development Environment and libraries for the OpenPOWER developer community. Additionally, IBM and Xilinx will continue to further utilize IBM's innovative Coherent Accelerator Processor Interface, or CAPI, to deliver accelerated computing value to its clients. CAPI, a unique feature built into the POWER architecture, provides Xilinx and the technology industry at large with the ability to build tightly integrated, coherent solutions right on top of the POWER architecture.
November 15, 2015
18:13 EDTAGNAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
November 13, 2015
14:41 EDTAGNAllergan presents EARLY analysis data at AAO meeting
Allergan announced that a post-hoc analysis of best corrected visual acuity data in diabetic macular edema patients treated with anti-vascular endothelial growth factor, or anti-VEGF, therapy suggests that long-term response in anti-VEGF treatment of DME can be assessed after three injections. Pravin Dugel, M.D., Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California and Managing Partner of Retinal Consultants of Arizona, said, "This data suggests that if treatment goals are not achieved after three injections, further expected improvement may be minimal and physicians may want to consider other treatment strategies."
11:57 EDTGOOGGoogle rolls out Chrome beta for iOS, 9to5Mac reports
Subscribe for More Information
11:12 EDTAGNPiper sees Pfizer profiting from Allergan deal, worth $50/share even without one
An acquisition of Allergan (AGN) by Pfizer (PFE) would increase the latter company's profits in 2016-2017 and lift its earnings by a large amount by 2019, wrote research firm Piper Jaffray in a note to investors today. WHAT'S NEW: By 2019, an acquisition of Allergan would increase Pfizer's earnings per share by 13%-16%, estimated Piper analyst Richard Purkiss. The deal would be profitable for Pfizer as early as 2016, the analyst believes. Excluding any acquisition, Pfizer is worth over $50 per share, well above analysts' average price target of $40, Purkiss believes. He kept a $52 price target and Overweight rating on Pfizer. WHAT'S NOTABLE: Yesterday dealReporter, noting that an acquisition of Allergan by Pfizer would be "a giant inversion deal," asserted that the U.S. Treasury could look to take steps to limit or discourage those types of transactions. On November 6, research firm Bernstein said that Allergan's strong results, coupled with the weakness of drug stocks, could cause Allergan to be reluctant to sell itself to Pfizer in the near-term. As a result, the firm thinks that the odds of a deal getting done may be lower than many believe. It kept a $385 price target and Outperform rating on Allergan. PRICE ACTION: In late morning trading, Pfizer rose fractionally to $33.47 and Allergan added 1.3% to $303.87.
10:49 EDTAGNMylan jumps, Perrigo plunges after hostile takeover bid fails
Shares of Mylan (MYL) jumped after the company's offer to acquire Perrigo (PRGO) failed. Perrigo shares fell after the news. WHAT'S NEW: Mylan's approximately $26B hostile takeover offer for Perrigo officially fell through Friday morning, ending a seven-month ordeal between the two companies. Mylan said that only about 40% of Perrigo's shares were tendered by the company's stockholders, falling short of the 50% required for an acquisition, forcing the offer to lapse after failing to meet its goal by the established deadline. In response to the news, Perrigo Chief Executive Officer Joseph Papa said he was "delighted" that his company's shareholders rejected the offer. "We have said all along that this offer from Mylan was a bad deal for our shareholders, as it significantly undervalued our durable business model and industry-leading future growth prospects," Papa said. Perrigo added that it will immediately commence its previously announced $2B share buyback and that it intends to complete $500M of the planned repurchase by the end of the year. WHAT'S NOTABLE: On July 27, Teva (TEVA) withdrew a takeover offer for Mylan amid Mylan's talks with Perrigo. The Israeli pharmaceutical company opted instead to purchase Allergan's (AGN) generics business. Commenting on its failure to buy Perrigo, Mylan Executive Chairman Robert Coury said in a statement that while the company viewed Perrigo as a "unique and exciting company," it was not required for the future success of the company. Coury said, "We are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified." STREET RESEARCH: Citi analyst Liav Abraham upgraded Mylan to Buy and raised her price target for shares to $59 from $52, saying that an overhang has been removed since the company's hostile attempt to buy Perrigo has fallen through. Abraham argued that a combination of the two companies would have been both destructive to both earnings and value for Mylan and that the failed bid will increase management's optionality to pursue other value-enhancing opportunities and enable investors to focus on the company's base business. In addition, RBC Capital Markets analyst Randall Stanicky confirmed a Sector Perform rating for both Mylan and Perrigo with price targets of $60 and $176, respectively. Stanicky said he expects Mylan's stock to gain 10%-15% towards $50 as a result of the news, while Perrigo will probably see a pull-back into the low $140s. The analyst added that the removal of the Mylan bid will drive initial weakness for Perrigo's shares but that the stock can settle close to its current levels. PRICE ACTION: In morning trading, Mylan rallied 12.5% to $48.60 and Perrigo fell 6.92% to $145.72. OTHERS TO WATCH: Teva shares trading in New York increased 0.26%, Allergan was up 0.66%, and Endo (ENDP), with which Reuters reported Perrigo held unsuccessful takeover talks, gained 5.56%.
08:22 EDTAGNAmerican Academy of Ophthalmology to hold annual meeting
AAO 2015 is being held in Las Vegas, Nevada on November 13-17 with webcasted presentations to begin on November 13 at 11:50 am. Webcast Link
06:54 EDTAGNPiper sees Pfizer worth over $50/share on standalone basis
Subscribe for More Information
November 12, 2015
18:58 EDTGOOGT-Mobile in preliminary talks to include YouTube in 'Binge On' service, WSJ says
Subscribe for More Information
13:45 EDTAGNPfizer, Allergan talks could set off further Treasury action, dealReporter says
Subscribe for More Information
13:24 EDTGOOGEarnings Watch: Cisco seeks to break out of trading rut with Q1 report
Cisco Systems (CSCO) is scheduled to report results of its fiscal first quarter after the market close on Thursday, November 12 with a conference call scheduled for 4:30 pm ET. Cisco, a member of the Dow Jones Industrial Average, sells Internet protocol-based networking and other products related to the communications and IT industry and provides related services. EXPECTATIONS: Analysts are looking for earnings per share of 56c on revenue of $12.65B, according to First Call. The consensus range for EPS is 55c-59c on revenue of $12.55B-$12.81B. Along with its quarterly report, Cisco guided to Q1 EPS of 55c-57c and said it expects its revenue to increase 2%-4% year over year. LAST QUARTER: On August 12, Cisco reported fourth quarter EPS of 59c on revenue of $12.8B, beating consensus estimates of 56c and $12.65B for EPS and revenue, respectively. NEWS: On its Q4 earnings conference call, Cisco said that it was looking at acquisitions at the right price, particularly in areas like software and security. On August 31, Apple (AAPL) and Cisco announced a partnership to build a "fast lane" for iOS business users by optimizing Cisco networks for iOS devices and apps, integrating iPhone with Cisco enterprise environments and providing unique collaboration on iPhone and iPad. The next day, Cisco was among multiple other companies, including Amazon (AMZN), Google (GOOG), Intel (INTC), Microsoft (MSFT), Mozilla, and Netflix (NFLX), announcing the formation of the Alliance for Open Media to build next-generation media formats, codecs, and technologies in the public interest. On September 3, Business Insider reported that people at Cisco still though that chairman John Chambers was running the show as chief executive officer after appointing Chuck Robbins to that role last May. On September 15, Mandiant, a FireEye (FEYE) subsidiary, said in a blog post that researchers discovered previously unknown attacks on certain routers and that such attacks replace the operating system used in Cisco equipment. About a week later, the Wall Street Journal reported that Cisco was aiming to strengthen its business in China by joining forces with Inspur group, a move which was confirmed on September 24. On October 29, Cisco announced its intention to acquire 1 Mainstream. CNBC later reported that the company paid $100M-$150M to acquire 1 Mainstream. On November 9, Ericsson (ERIC) and Cisco announced a global business and technology partnership to "create the networks of the future." The companies said that the strategic partnership will be a key driver of growth and value for the next decade, with each company benefiting from incremental revenue in calendar year 2016 and expected to ramp to $1B or more for each by 2018. STREET RESEARCH: On August 17, Morgan Stanley downgraded Cisco to Equal Weight from Overweight and maintained a $30 price target on the stock, saying it did not believe improved growth is "secular" and anticipates growth will revert to GDP like levels as the upgrade cycle concludes. Wells Fargo said on August 28 that a 10% selloff in communication tech stocks, including Cisco, had created an attractive buying opportunity. Bernstein said a week later that Cisco, Juniper (JNPR), and F5 Networks (FFIV) should be bought on wider macro economic weakness. On October 6, Citi initiated coverage of Cisco with a Buy rating and $30 price target. A week later, Barclays initiated coverage of Cisco with an Overweight rating and a $32 price target. On November 9, RBC Capital maintained an Outperform rating and $33 price target on Cisco, saying it expects the company to report slightly better than expected results. The next day, SunTrust maintained a Buy rating on Cisco, saying its partnership with Ericsson was a positive and should strengthen Cisco's service provider business. PRICE ACTION: In afternoon trading ahead of tonight's report, Cisco shares were up 0.5% to $27.97. In the last three months, Cisco shares are fractionally higher and virtually unchanged when discounting this afternoon's slight rise.
12:38 EDTGOOGYouTube launches Music app
YouTube has launched the YouTube Music app for iOS and Android. In a blog post, the company commented, YouTube is offering a free 14-day trial of premium mode. "No matter where you start in the app, the music will never stop. Every song you play or artist you choose will take you on an endless journey through YouTube's music catalog. A simple tap and you're on your way, enjoying your favorite music and discovering new artists effortlessly. The home tab will recommend tracks just for you and create personalized stations based on your tastes." Reference Link
09:19 EDTGOOGPayPal sinks with Apple eyeing peer-to-peer payments
Shares of PayPal (PYPL) are weak again this morning following a report yesterday afternoon alleging that Apple (AAPL) is set to launch a competitor to one of the payment technology company's offerings. Analysts that were already split about PayPal's prospects are also divided on the potential impact of Apple's entry, with a bull at Citi downplaying the risk and a bear at Piper Jaffray voicing greater concern. APPLE COMPETITION: Apple is in talks with U.S. banks to create a mobile person-to-person payment service, reported The Wall Street Journal yesterday afternoon, citing people familiar with the matter. Apple's service, which would likely be linked to the company's Apple Pay system and could get off the ground next year, would compete with PayPal's Venmo peer-to-peer, or P2P, payment platform, the Journal said. BULLISH TAKE: Citi analyst Ashwin Shirvaikar says his Buy thesis on PayPal is unchanged after the Journal's report regarding Apple's efforts. Apple is a "viable competitor in a crowded field," but its product is unlikely to change the near-term growth trajectory of PayPal's Venmo, Shirvaikar told investors in a research note. He keeps a Buy rating on PayPal with a $44 price target. BEARISH TAKE: Piper Jaffray analyst Gene Munster believes Apple's reported plans for a P2P payment offering sometime in 2016 will have limited to no impact on his model for the iPhone maker, but cautions that more mobile wallets offering P2P will add to the challenges facing PayPal's Venmo. The analyst believes the "real estate for all logos at the point-of-sale will be scarce and cluttered," noting that in addition to new entrants like Apple Pay, Samsung Pay, Google's (GOOG) Android Pay, JPMorgan's (JPM) Chase Pay, MCX/CurrentC and PayPal there are still legacy players such as Visa (V) Checkout, MasterCard (MA) Masterpass, and American Express' (AXP) Express Checkout. Munster thinks Venmo is a strong offering that will keep gaining share, but in addition to competition, he sees low interest rates hindering float income and thinks the value proposition for consumers and merchants remains "uncertain." The analyst keeps an Underweight on PayPal, which is the firm's equivalent of a "sell" rating, with a $30 target for its shares. PRICE ACTION: Shares of PayPal slipped 1.8% to close at $36.33 yesterday following the Journal's report. In pre-market trading, the stock fell another 1% to $36 per share.
07:43 EDTFSLRFirst Solar management to meet with Deutsche Bank
Subscribe for More Information
05:40 EDTIBMIBM, HCL Technologies announce strategic partnership
IBM and HCL Technologies announced a strategic partnership to jointly build hybrid cloud solutions to help enterprises drive their digital transformations. HCL will use Bluemix, IBM's Cloud platform to build applications and solutions in the areas of Unified Service Management and Internet of Things. HCL will also use IBM Cloud's Infrastructure as a Service, SoftLayer, to offer cloud-based solutions to its clients.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use